Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.

Molecular Cytogenetics Group, Human Cancer Genetics programme, Centro Nacional Investigaciones Oncologicas, Centro de Investigaciones de Enfermedades Raras, Madrid, Spain.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K (Impact Factor: 10.16). 01/2012; 26(6):1329-37. DOI: 10.1038/leu.2011.376
Source: PubMed

ABSTRACT The AML1-ETO fusion protein, which is present in 10-15% of cases of acute myeloid leukemia, is known to repress myeloid differentiation genes through DNA binding and recruitment of chromatin-modifying proteins and transcription factors in target genes. ChIP-chip analysis of human hematopoietic stem/progenitor cells transduced with the AML1-ETO fusion gene enabled us to identify 1168 AML1-ETO target genes, 103 of which were co-occupied by histone deacetylase 1 (HDAC1) and had lost the hyperacetylation mark at histone H4, and 264 showed a K9 trimethylation at histone H3. Enrichment of genes involved in hematopoietic differentiation and in specific signaling pathways was observed in the presence of these epigenetic modifications associated with an 'inactive' chromatin status. Furthermore, AML1-ETO target genes had a significant correlation between the chromatin marks studied and transcriptional silencing. Interestingly, AML1 binding sites were absent on a large number of selected AML1-ETO promoters and an Sp1 binding site was found in over 50% of them. Reversible silencing induced by the fusion protein in the presence of AML1 and/or Sp1 transcription factor binding site was confirmed. Therefore, this study provides a global analysis of AML1-ETO functional chromatin modifications and identifies the important role of Sp1 in the DNA binding pattern of AML1-ETO, suggesting a role for Sp1-targeted therapy in this leukemia subtype.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The MYB oncogene is widely expressed in acute leukemias and is important for the continued proliferation of leukemia cells, suggesting that MYB may be a therapeutic target in these diseases. However, realization of this potential requires (i) a significant therapeutic window for MYB inhibition, given its essential role in normal hematopoiesis; and (ii) an approach for developing an effective therapeutic. We previously showed that the interaction of Myb with the coactivator CBP/p300 is essential for its transforming activity. Here we show, using cells from Booreana mice which carry a mutant allele of Myb, that this interaction is essential for in vitro transformation by the myeloid leukemia oncogenes AML1-ETO, AML1-ETO9a, MLL-ENL, and MLL-AF9. We further show that unlike cells from wild-type mice, Booreana cells transduced with AML1-ETO9a or MLL-AF9 retroviruses fail to generate leukemia upon transplantation into irradiated recipients. Finally, we have begun to explore the molecular mechanisms underlying these observations by gene expression profiling. This identified several genes previously implicated in myeloid leukemogenesis and HSC function as being regulated in a Myb-p300-dependent manner. These data highlight the importance of the Myb-p300 interaction in myeloid leukemogenesis and suggest disruption of this interaction as a potential therapeutic strategy for AML.
    Blood 03/2014; DOI:10.1182/blood-2012-02-413187 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AML1/ETO and MLL fusion proteins are among the most common chimeric transcription factors created by chromosomal translocations in acute myeloid leukemia (AML) whose pathogenic roles involve perturbations of epigenetic mechanisms of gene regulation. AML1/ETO is caused by the t(8;21) translocation and is present in approximately 12–15 % of AMLs. It acts as an epigenetic modifier by aberrantly recruiting histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) to target promoters and repressing the expression of its subordinate genes. AML1/ETO-induced epigenetic modifications may be reversed by both HDAC and DNMT inhibitors, restoring the expression of inappropriately silenced genes. Diverse MLL fusion proteins are created by a remarkable variety of translocations involving chromosome band 11q23 in approximately 10 % of AMLs. MLL fusion proteins promote constitutive expression of target genes through various mechanisms involving aberrant recruitment of transcriptional elongation factors (P-TEFb, ELL), chromatin-modifying acetyltransferases (CBP, P300), or histone methyltransferases (DOT1L, PRMT1). Selective targeted inhibition of MLL-associated factors that write or read the histone modifications in chromatin of MLL target genes displays promising efficacy in preclinical studies.
    Epigenetic Therapy of Cancer, Edited by Michael Lübbert, Peter A. Jones, 01/2014: pages 121-144; Springer., ISBN: 978-3-642-38404-2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Protein/protein interactions (PPIs) are essential for all biological processes. Their role as central control switches and checkpoints in signaling and regulation makes their dysfunction an eminent cause of cancer and other diseases. Thus, a target-oriented intervention with PPIs, in particular by small molecules suitable for a pharmacological therapy, is the object of intense research. In the recent years, this research of PPIs yielded a number of low-molecular protein/protein interaction modulators (PPIMs). However, only a few PPIMs were identified by rational or structure-based considerations. The reason is that it is difficult to directly re-use well-established computational methods to identify ligands of conventional targets, such as enzymes, receptors, or transporters. Conventional targets naturally bind small molecules via pronounced complementary binding pockets. In contrast, many protein/protein interfaces (PPIfaces) are large and lack pronounced pockets. Thus, it is hard to find small molecules with an affinity and specificity that is adequate to displace one of the binding proteins. Nevertheless, the widespread discovery of (drug-like) PPIMs shows: these challenges can be overcome, and PPIs are not undruggable in general. The goal of this thesis was to develop a computational strategy for the rational identification of PPIMs, notably of NHR2 inhibitors, starting only with a protein/protein complex structure (PPI structure). This task subdivides into the four core themes of this thesis. First, I reviewed the knowledge about PPIs, PPIMs, the determinants of their interactions as well as computational methods for the identification of druggable sites and PPIMs. Second, I implemented a strategy that uses a PPI-structure based prediction of hot spots and transient pockets to guide a structure-based virtual screening. As a validation, I retrieved known PPIMs that bind to the PPIface of interleukin-2 from a large set of non-binders. Third, I analyzed the potential of teroxazoles as a new class of hydrophilic α-helix mimetics. These present side chains similar to α-helices and mimic a sequence pattern that has not yet been considered. Fourth, I identified the first micromolar inhibitors of the NHR2-mediated tetramerization of RUNX1-ETO (RE) from dimers, a prerequisite for the onset and maintenance of RE-dependent acute myeloid leukemia (RE-AML). Predicted tetramerization hot spots close to the largest pocket in the PPIface guided the computational identification of drug-like PPIMs. These PPIMs mimic NHR2 hot spots, aim at the PPIface, and inhibit dimer association as well as the proliferation of RE-dependent cells. These PPIMs are valuable as probes and tools to study the effects of NHR2 tetramerization and are an important step towards a personalized therapy of RE-AML. Most importantly, however, the presented strategy can well be the first step in any comparable structure-based endeavor to identify or design PPIMs, even in cases where only a PPI structure with a rather flat PPIface is known.
    10/2014, Degree: Dr. rer. nat. (PhD), Supervisor: Holger Gohlke


Available from
May 21, 2014